Migraine treatment in thailand: what helps and hinders eptinezumab use?

NCT ID NCT07035197

Completed Knowledge-focused Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how migraine patients and healthcare providers in Thailand experience eptinezumab, a preventive migraine infusion given every 3 months. Researchers interviewed 30 participants to find out what makes it easier or harder to use this treatment in a real-world hospital setting. The goal is to improve migraine care and access to new therapies in middle-income countries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eptinezumab
What this could lead to: If successful, this study could help improve access to eptinezumab for migraine patients in Thailand and similar countries.
What could go wrong: This is a small, completed observational study (30 participants) that gathers opinions and experiences, not a large trial testing effectiveness. Results may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder Treatment Refusal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE TREATMENT TREATMENT REFUSAL

Contacts and locations

Locations

King Chualongkorn Memorial Hospital, the Thai Red Cross Society

Bangkok, 10330, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.